1. Acknowledgement to Referees

   Acknowledgement to Referees 18 December 2023 Pages: 1 - 3

2. The Inflation Reduction Act: Hope for Prescription Drug Prices in the USA

   • Lindsay Allen

   Editorial 06 October 2023 Pages: 5 - 7

3. Modelling Informal Carers’ Health-Related Quality of Life: Challenges for Economic Evaluation

   • Becky Pennington
   • Hareth Al-Janabi

   Current Opinion Open access 10 November 2023 Pages: 9 - 16

4. A Systematic Review of the World’s Largest Government Sponsored Health Insurance Scheme for 500 Million Beneficiaries in India: Pradhan Mantri Jan Arogya Yojana

   • Aashima
   • Rajesh Sharma

   Systematic Review 06 October 2023 Pages: 17 - 32

   

5. Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review

   • Yan Li
   • Pingyu Chen
   • Hongchao Li

   Systematic Review 29 October 2023 Pages: 33 - 48

   

6. Exploratory Approach to Incorporating Carbon Footprint in Health Technology Assessment (HTA) Modelling: Cost-Effectiveness Analysis of Health Interventions in the United Kingdom

   • Max Kindred
   • Zahratu Shabrina
   • Neily Zakiyah

   Original Research Article Open access 10 November 2023 Pages: 49 - 60

   

7. Societal Cost of Racial Pneumococcal Disease Disparities in US Adults Aged 50 Years or Older

   • Shoroq M. Altawalbeh
   • Angela R. Wateska
   • Kenneth J. Smith

   Original Research Article 15 November 2023 Pages: 61 - 71

   

8. Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy

   • Constanza Vargas
   • Rebecca Addo
   • Stephen Goodall

   Original Research Article 11 November 2023 Pages: 73 - 84

   

9. Cost-Effectiveness of the Second COVID-19 Booster Vaccination in the USA

   • Rui Li
   • Pengyi Lu
   • Lei Zhang

   Original Research Article 01 November 2023 Pages: 85 - 95

   

10. VOLY: The Monetary Value of a Life-Year at the End of Patients’ Lives

    • Elizabeta Ribarić
    • Ismar Velić
    • Ana Bobinac

    Original Research Article 04 October 2023 Pages: 97 - 106

    

11. Cost Effectiveness of Molecular Diagnostic Testing Algorithms for the Treatment Selection of Frontline Ibrutinib for Patients with Chronic Lymphocytic Leukemia in Australia

    • Martin Vu
    • Koen Degeling
    • Maarten J. IJzerman

    Original Research Article Open access 22 August 2023 Pages: 107 - 122

    

12. Comment on: “The Assessment of Patient-Reported Outcomes for the Authorisation of Medicines in Europe: A Review of European Public Assessment Reports from 2017 to 2022”

    • Sieta T. de Vries
    • Noral Huda S. Al-Mugoter
    • Peter G. M. Mol

    Research Letter 16 November 2023 Pages: 123 - 124

13. Comment on: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”

    • Afschin Gandjour

    Letter to the Editor Open access 02 December 2023 Pages: 125 - 126

14. Authors’ Reply to Gandjour: “10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?”

    • Melanie Büssgen
    • Tom Stargardt

    Letter to the Editor Open access 02 December 2023 Pages: 127 - 128